| 초록 |
Computed tomography (CT) is one of the diagnostic devices. However, it is hard to diagnose disease in soft tissues. So, CT contrast agents are crucial to improve CT contrast image for soft tissues. Bile duct imaging is generally performed endoscopic retrograde cholangiopancreatography (ERCP). But, ERCP is an invasive method for patients. Resolving disadvantage of ERCP, we developed liver targetable CT contrast agent (LTCC). LTCC is composed with iodine-based molecule, liver targeting molecule, and solubility enhancing moiety. We confirmed in vitro specific binding and uptake of LTCC hepatocytes (receptor positive) and non-hepatic cells (receptor negative). We also have confirmed in vivo biodistribution of LTCC and confirmed the iodine content of bile juice in comparison with the usually available contrast agent (UACA). We have confirmed contrast effect in CT image at bile duct and have confirmed elimination of LTCC by detecting LTCC content in urine and feces. |
